<DOC>
	<DOCNO>NCT00883194</DOCNO>
	<brief_summary>This clinical study test PRF-108 PRF-110 ( new extend release 4 % gel formulation ropivacaine ) experimentally induced pain model healthy volunteer . PRF-108 PRF-110 design deliver slow release ropivacaine 72 hour . The purpose study investigate safety ( side effect occurs ) associate single administration PRF-108 PRF-110 evaluate analgesic effect experimentally induce pain model compare ropivacaine Solution 0.5 % Vehicle Gel .</brief_summary>
	<brief_title>A Safety Effectiveness Pilot Study PRF-108 PRF-110 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ropivacaine</mesh_term>
	<criteria>1 . Male subject 1860 year age ; 2 . Subjects within Â±10 % ideal body weight/height ( base frame size ) give Metropolitan Life Insurance Tables ; 3 . Subjects ASA Category I normal physical health judge physical laboratory examination negative urine base screen drug abuse ; 4 . Subjects must agree refrain ingest analgesic medication 3 day 5 halflives drug prior study period alcohol 1 day prior study period ; 5 . Subjects tolerate 0.5mL injection saline low back area . 6 . The subject capable reading , comprehend , sign informed consent form . 1 . Subjects history significant hepatic , renal , endocrine , cardiac , neurological , psychiatric , gastrointestinal , pulmonary , hematologic , metabolic disorder , include glaucoma , diabetes , emphysema , chronic bronchitis ; 2 . Subjects history type cancer ; 3 . Subjects condition affect absorption , metabolism , passage drug body , ( e.g. , sprue , celiac disease , Crohn 's disease , colitis , liver , kidney , thyroid condition ) ; 4 . Subjects history alcohol substance abuse ( include positive drug screen test ) ; 5 . Subjects currently history hypertension ; 6 . Subjects know hypersensitivity local anesthetic drug ; 7 . Subjects history benign prostatic hyperplasia difficulty urination ; 8 . Subjects hematocrit level normal range screen laboratory examination ; 9 . Subjects clinically significant abnormal lab result ( judge Principal Investigator ) ; 10 . An abnormal ECG screen include PR &gt; 200 m , QRS &gt; 110 m , QTcF &lt; 380 &gt; 400 m , lead II T wave abnormality . Nonspecific T wave abnormality lead lead II permissible accompany morphological abnormality . 11 . Subjects condition history felt Investigator place subject increase risk ; 12 . Subjects smoke chewed tobaccocontaining substance within 6 month prior start study ; 13 . Subjects judge Investigator unable unwilling comply requirement protocol ; 14 . Subjects use investigational drug within 30 day prior enter study ; 15 . Subjects donate blood within 3 month prior start study ( include blood donation relate surgical procedure ) ; 16 . Subjects previously participate trial ; 17 . Subjects member study site staff directly involve study relative Sponsor personnel involve study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Experimental Pain Model</keyword>
</DOC>